Showing posts with label ID. Show all posts
Showing posts with label ID. Show all posts

Tuesday, May 17, 2011

Pre exposure prophylaxis for HIV

A homosexual male who is an iv drug abuser walks into the office...asking ways to help him prevent contacting HIV..with his high risk behaviour!! Apart from advising on safe sex and risks of sharing needles(which are most important..and at the same time cannot be relied at all times due to non adherence)....do we have any medications to offer him??


Lets look at the iPREX study published in NEJM Dec 2010. This was a placebo-controlled, double-blind, randomized trial involving 2499 subjects(men who have sex with men) to see if a combination of Emtricitabine-Tenofivir(FTC-TDF) once daily reduced the incidence of HIV over a f/u period of 1.2 years. Of the 100 incident HIV infections during the study period, 64 occurred in the placebo group and 36 in the FTC–TDF group, with an efficacy of 44% and a 95% CI of 15 to 63. An important finding to note is that, in the FTC–TDF group, the study drug was pharmacologically detected in 51% of subjects who remained free of HIV infection but in only 9% of those who became infected. So exposure to FTC–TDF was associated with a reduction in HIV acquisition. Main issues in putting this into practice has a few concerns. Few of them are drug adherence(very poor in the study), long term outcome, side effects(quite a few in the study drug group had renal impairement which rverted to normal on discontinuation of drug!). All these issues have been nicely discussed in the letter following the study( another arrow in the Quiver.NEJM Dec 2010)
Now the trial has been extended to look for long term outcomes and ways to improve adherence. results are expected by 2013.(HIV & TB News)


An earlier study , CAPRISA 004 in which a total of 889 sexually active, HIV-uninfected women (age range, 18–40) received either 1% tenofovir gel or placebo gel, with instructions to administer the gel intravaginally within 12 hours before sex and also within 12 hours after sex. Mean follow-up was 18 months.The incidence of HIV was 5.6 /100 person-years in the tenofovir group versus 9.1 /100 person-years in the placebo group, for an incidence rate ratio (IRR) of 0.61 (95% CI, 0.40–0.94; P=0.017). Shows promise for pre exposure prophylaxis.


In this context ...FEM-PrEP trial has to be mentioned. This study evaluated if oral daily FTC-TDF prevented HIV in a group of high risk women. The study was stopped last month after an interim analysis didnt find any benefit compared to placebo.(AVAC April 2011). Full analysis of trial should be available shortly.(may be related to adherence issues!!)


VOICE trial - Vaginal and Oral Interventions to Control the Epidemic .........is an ongoing study on high risk women comparing FTC-TDF, tenofovir tablet alone , or tenofovir gel. This study might shed light into ..which of these will be more effective. By this time we will also have the long term safety and compliance outcomes on the i-PREX study.
May be 2013 might be a year the world would see a...  'HIV prevention pill'  !!!

Monday, April 25, 2011

Norepinephrine or Dopamine?

It looks like...we may have a winner. Yes
Im talking about the use of vasopressors in the setting of septic shock. There have been a few clinical trials done to see if one vasopressor is better than the other in terms of mortality from septic shock. (the latest one was from SOAP 2 trial from NEJM 2010)We didnt have a clear result so far.

But  a recent meta analysis of the trials have shown that norepinephrine might be better than Dopamine. It is associated with a 9% reduction in in-hospital and 28 day mortality in patients with septic shock. Patients on Dopamine had significantly increased incidence of cardiac arrhythmias compared to norepinephrine. This is probably the reason behind the poor performance of Doapmine...as we all know that arrhythmias can hinder cardiac function. The same finding of increased cardiac arrhythmias with Dopamine was also noted in the above SOAP trial.
The above meta-analysis was done at Thomas Jefferson University.(J of Int Care Med ...March 2011)

Would be reasonable to use nor-epinephrine as the first line vasopressor for patients with septic shock. Infact according to the SOAP trial,dopamine was associated with an increased 28 day mortality in patients with cardiogenic shock, as compared to norepinephrine!

Saturday, April 23, 2011

The "Duty to warn" !!

We had a young female with HIV for 10 years,who came with an infected condyloma. She has had previous MAC, vulval cancer and cervical dysplasia  in the past. She has been with her partner for last 1 year, and they are sexually active,and use protection everytime. But when enquired, she said that the partner does not know about her HIV status , and she did not want to disclose this to him .Now.......do we have to honour her wish or...do we have to let the partner know?? Lets see what Connecticut law tells us.....(beware..this may not be true for other states!)

The term “duty to warn” refers to situations in which a  physician may learn that a patient is engaging in unsafe sex without having disclosed his or her HIV-positive status to the partner.
Connecticut law permits both public health officers and physicians, under certain circumstances, to inform or warn partners that they may have been exposed to HIV.The term “partner” means an “identified spouse or sex partner of the protected individual or a person identified as having shared hypodermic needles or syringes with the protected individual.” The requirements for such a disclosure by a public health officer are that:

1.There is a reasonable belief of a significant risk of transmission to the partner.
2.The public health officer has counseled the individual regarding the need to notify a partner and reasonably believes that the individual will not disclose to the partner; and
3.The public health officer has informed the protected individual of his or her intent to make the disclosure.

A physician may only warn or inform a known partner if both the partner and the individual with HIV are under the physician’s care. A physician may also disclose confidential HIV related information to a public health officer for the purpose of warning partners, if the physician takes the same steps with respect to his or her patient as public health officers must take above.
In making such a warning, the physician or public health official shall not disclose the identity of the HIV-infected individual and, where practicable, shall make such disclosure in person.
Well...this is still an evolving area of ethics, and might change in the future. Hope this helps.....and this is a sensitive issue to be dealt.

Thursday, April 14, 2011

Spontaneous bacterial peritonitis

An acute bacterial infection of ascitic fluid. Happens in people with ascites due to any etiology(even with CHF, Budd chiari !!!). The route of infection is still not entirely clear. It may be a simple translocation of bacteria from the gut due to bacterial overgrowth  (as previously thought), or from hematogenous spread. But in general its the gut bacteria which accounts for most of SBP. This is mainly due to reduced intestinal transit times in pts with cirrhosis, along with low protein and complement levels etc.
The common bugs are E.Coli, Klebsiella and Strep pneumoniae.
Diagnosis is based on diagnostic aspiration of the ascitic fluid. We all tap the ascitic fluid in someone with symptoms of infection(fever, abdominal pain, tenderness etc). But around 30% of pts with SBP might not have any symptoms!! So...what shall we do?.........One of our gastroenterologist says...."JUST TAP ALL ASCITES". Well...he might be right...given a mortality range of 30-70% for SBP!


Based on the tap....it can be classified as follows...
1.SBP - if >250 PMN/micL  AND positive culture.
2.Culture-negative neutrocytic ascites -ascitic fluid culture is negative, but PMN count is ≥ 250 cells/µL. 
3. Monomicrobial nonneutrocytic bacterascites - positive culture result with a PMN count ≤ 250 cells/µL.
Irrespective of what type it is!!!......they all need to be treated based on clinical suspicion.


A very simple method being used these days(mostly in Europe) to diagnose SBP is the simple Leukocyte esterase test, which can be done at bedside. It has a sensitivity & specificity of 100 % & 91% resp to diagnose SBP! ( E Jof Gastro Hep 2007)
What to treat with -- A 3rd generation Cephalosporin or a fluroquinolone. Its rare to have anaerobic SBP , as ascitic fluid is rich in Oxygen!


When to use albumin - One of the main causes of mortality in SBP is due to development of renal failure. Albumin in addition to antibiotics have shown to prevent renal impairment and also to reduce mortality by around 10 to 15%based on this randomised trial(NEJM 1999). Its given as 1.5 g/kg at diagnosis and 1 g/kg on Day3.There is another randomised trial underway in Brazil to add more evidence to this practice.(ALTERNATE trial). 


Prohylaxis for SBP - Well..there are a group of patients who will benifit from prophylaxis. They are 1.anyone with a previous episode of SBP reducing mortality by 25% over a 1 year period(Hepatology 1990)  2. GI bleed with a course of 7 days.  3.pts with ascitic fluid protein <1 g/dl plus one of the following --- creatinine >1.5, bilirubin>4.(Hepatology 1995) The last criteria is a soft call, and would depend on local practice.The last two indications are a short course(1 -2 weeks) of antibiotics.The first indication is a longer term prophylaxis (1 year or more). Norfloxacin 400 daily is a preferred drug(as it selectively targets Gram negatives, and leaves anaerobes !)

Monday, April 11, 2011

VRE ...when to treat!!

Vancomycin resistant enterococci are emerging as another leading nosocomial bacteria in hospitals.Enterococci are gram-positive and facultatively anaerobic microorganisms commonly found as part of the normal flora in the gastrointestinal tract.Several factors contribute to this increased risk among hospitalized patients, such as the disruption of the normal gastrointestinal flora by administration of broad-spectrum antibiotics, colonization with hospital-associated strains, poor infection control practices, presence of indwelling devices including urinary catheters, and an immunosuppressed state.Enterococcus faecalis andEnterococcus faecium are the two most common species isolated in this setting. The most common types of infection caused by enterococci are urinary tract infections (UTIs)


Given this intro...there may be 3 clinical scenarios we come across in hospital practice...
1. VRE UTI                 2. aymptomatic VRE bactereuria         3.VRE colonization
Well ..these have to be differentiated in clinical practice, as the last 2 dont need treatment , except in some special circumstances.


 A good detailed history about UTI symptoms in very much the deciding step for who to treat. Any lower or upper UTI system is needed to suspect UTI from VRE( except in elderly pts ). Once this is present, then proceed according to the flow sheet above.Evidence of VRE in the urine in the absence of symptoms or pyuria may have limited clinical importance in most patients, representing asymptomatic VRE bacteriuria or colonization, and generally does not require treatment; however, treatment may be considered in very high-risk patients (e.g., patients with catheter-acquired bacteriuria that persists 48 hrs after indwelling catheter removal, patients with planned genitourinary procedures, solid organ transplant recipients, neutropenic patients, and pregnant women).Always change Foley catheters once VRE is found in the urine.


 Aminopenicillins, both with (e.g., ampicillin-sulbactam, amoxicillin-clavulanate) or without β-lactamase inhibitors and penicillin are generally considered to be the drugs of choice for the empiric treatment of VRE infections.In case of ampicillin resistance , then nitrofurantoin or Linezolid can be used for VRE cystitis...........and Daptomycin or Linezolid can be used for upper tract UTIs and VRE bactermia. Duration of treatment doesnt need to be extended beyond 14 days.

Monday, January 24, 2011

Does Cranberry Juice Prevent Recurrent UTI ?


As we all know....cranberry juice has been thought to prevent UTIs. No we have a randomised controlled trial to answer the above question. Reasearchersa at Michigan conducted a double blind trial on women 18 - 40 years of age who presented with with UTIs over a 2 year period.


There were 319 participants who were randomized to receive 8 ounces twice daily of placebo juice or of low-calorie cranberry juice cocktail standardized for its concentration of proanthocyanidin (the active ingredient). A clean-catch urine sample was collected for culture at baseline, 3 months, and 6 months, and at visits associated with UTI episodes. During the 6-month follow up, 54 culture-confirmed recurrent UTI episodes were observed. The recurrence rate — 16.9% overall — was 19.3% in the cranberry juice group and 14.6% in the placebo group (P=0.21).

These findings and the don't show any reduction in the recurrence of UTI among reproductive age group females. However, as the authors point out, something other than proanthocyanidin might be the active factor, and the placebo might inadvertently have contained this ingredient. Therefore, this study is probably not the last nail on cranberry juice and UTI prevention.In fact the 2008 cochrane review 
showed a small reduction in UTI over a 12 month period.


After an initial urinary tract infection (UTI), 24% of otherwise healthy women aged 18 to 39 experience a recurrence within 6 months, and 5% of women have multiple recurrences within 1 year. Cranberry juice is a well-known folk remedy for preventing UTI, and in vitro experiments have suggested that cranberries decrease the adherence of Escherichia coli to the uroepithelium.

All this study shows is that proanthocyanidin may not be the active ingredient behind UTI prevention ! Given the inability to prove or disprove this theory........it will be ok to take cranberry juice....as it doesnt cause any harm.

Monday, December 6, 2010

Dengue in India - wake up

Well...well...well.......I was little busy with my ICU rotation this month....and in the middle of it...I had to rush to India as my grandmother was taken ill to the hospital with Dengue. I should say...that people in US & Europe should be praising their government for giving them an extraordinary health system with excellent doctors and nurses. Anyway...... I wanted to write a lilttle about Dengue (this is almost non existent in Europe...and present along the mid south and south west of US)

Dengue, caused by the bite of Aedes mosquito (for some reason the worse bites are during the day) comes in three forms - 1. Dengue fever (most common type - mild symptoms lasting a week or so without any complications)  2. Dengue Hemorrhagic fever - complicated by thrombocytopenia and bleeding from mucosa.
3. Dengue shock syndrome - characterised by circulatory shock (mortality is 6 - 30% ).

A quick pathophysiology - The main pathophysiology is capillary leak and thrombocytopenia...both occuring after the fever has abated..and lasting for 2-3 days.So the critical period is those 2-3 days after fever and rigors settle down. Because of the capillary leak....there will be an increase in hematocrit(a >20% increase from baseline is significant). If supportive measures are not taken...this will proceed to circulatory shock needing careful fluid replacement.....as excessive replacement will worsen capillary leak and enhance third spacing(pleural, ascitic & pericardial)
The management is entirely supportive. Most can be managed as outpatients provided they check their platelet & hematocrit after their fever stops. Patients with thrombocytopenia need to be monitored in hospital for need for transfusions and prevention of complications including coagulopathy,bleeding into internal organs and circulatory shock. One other complication which has been reported to be present in around 40% of dengue patients is hyponatremia. The reason for this has been postulated to be hypovolemia with some SIADH. replacement with 0.9% NS would help correct it.

There have been many cases of Dengue so far...and still no action has been taken to get rid of the Aedes. Common India.......act quick.

Monday, November 15, 2010

PCP prophylaxis in non-HIV patients

Many clinicians routinely prescribe sulfamethoxazole-trimethoprim (SMX-TMP) or another agent to prevent the development of Pneumocystis jirovecii pneumonia (PCP) in patients receiving immunosuppressive medications, with the assumption that the risks are same as some one who is immunosuppressed from HIV. Evidence justifying such a policy is sparse.
A recent study published in J Am Acad Dermatology tried to find the right way to do this. The authors of this retrospective study examined the frequency of PCP in 198 HIV-negative patients who received immunomodulatory medications for dermatologic disorders, such as psoriasis, dermatomyositis, vasculitis, and pemphigoid.
Systemic corticosteroids, methotrexate, antimalarials, and azathioprine were the most common immunosuppressive medications used by these patients; approximately 25% received a biologic agent, such as etanercept. About 25% were concurrently receiving a prophylactic medication to prevent PCP. During an average follow-up of 8 years, PCP developed in only one patient (94 years old) not receiving PCP prophylaxis (0.7% incidence). Serious reactions to the PCP-preventive medication developed in 6% of SMX-TMP recipients and 37% of dapsone recipients.
The very low risk for PCP is too small to justify routine prophylaxis. In addition to their expense, these medications are frequently associated with adverse effects. The authors sensibly recommend that clinicians avoid routine prophylaxis in patients receiving immunosuppressive agents and that we remain alert to the uncommon possibility of PCP, especially in those with apparent risk factors, which include age >60, concurrent pulmonary disease, leukopenia, hypoalbuminemia, and CD4 counts <300/dL.
This above issue was brought on by one of my colleagues, Dr.Dioverti.. during a friendly chat ...as she had a patient on bactrim prophylaxis due to chronic steroid use. This study will help those questions for now.